tpi-1

TPI-1 is a SHP-1 inhibitor.

TPI-1020 is a novel anti-inflammatory corticosteroid and nitric oxide (NO) donor derived from budesonide. It exhibits a concentration-dependent bronchodilatory effect mediated by released NO through a cGMP-dependent pathway. Studies suggest that TPI-1020 combines corticosteroid activity with NO release, potentially benefiting the treatment of acute bronchoconstriction events in asthma and allowing for a reduced dose of inhaled beta(2)-adrenoceptor agonists.

TPI-1917-49 is a promising amyloid reducing agent that works by reducing Aβ levels.

Tipiracil hydrochloride (MA-1 hydrochloride) is a thymidine phosphorylase inhibitor (TPI). Tipiracil hydrochloride is one of the active components in TAS-102, which is an anticancer drug candidate currently in clinical trials.

Triosephosphate isomerase (TPI), a glycolytic enzyme, efficiently catalyzes the interconversion between dihydroxyacetone phosphate and D-glyceraldehyde-3-phosphate. The catalytic site of TPI is located at the dimer interface [1].